Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Combination of Elektrofi's ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in patient-centric drug delivery innovation Combination of Elektrofi's ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in patient-centric drug delivery innovation

Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement

Novo Nordisk

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative.

Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers

Eli Lilly's diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.

Eli Lilly Is Waiting for Obesity-Drug Approval. Here's How Much It Could Be Worth.

Vertex Pharmaceuticals

Eli Lilly's growth is just getting started. Novo Nordisk shows no signs of slowing down, thanks to soaring sales of Ozempic and Wegovy.

3 Unstoppable Stocks to Buy Sooner Rather Than Later

-  In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection ( RET) fusion-positive non-small cell lung cancer (NSCLC) - In the Phase 3 LIBRETTO-531 study, Retevmo provided a 72% improvement in PFS compared to cabozantinib or vandetanib in patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) INDIANAPOLIS , Oct. 21, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® (selpercatinib) versus platinum-based chemotherapy — with or without pembrolizumab — as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), and the LIBRETTO-531 Phase 3 study, which evaluated Retevmo versus multikinase inhibitors (MKIs) in patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). In both clinical studies, results were based on pre-specified interim efficacy analyses conducted by independent data monitoring committees (IDMC).

Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 202

Get ready for Ozem-kids! The pharmaceutical companies behind Ozempic, Mounjaro and Wegovy — which have exploded in popularity with adults looking to lose weight — are testing whether the drugs are safe for children.

Pharma firms testing weight loss drugs for kids amid Ozempic craze

Eli Lilly and Co (NYSE:LLY) is planning a trial of its diabetes drug Mounjaro in patients with obesity as young as six years old according to a Bloomberg report Friday citing a person familiar with the matter. The company is already carrying out a Phase 3 trial of the drug in children as young as 10 years old and teenagers with type 2 diabetes.

Eli Lilly planning diabetes drug trial for children six years and older: report

INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement

Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% at 5 years These data reinforce two years of Verzenio plus endocrine therapy as the standard of care for these patients in this curative setting Use of Verzenio as a treatment option in this setting is supported by an NCCN® Category 1 designation INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years of adjuvant Verzenio® (abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. These data were shared in a late-breaking presentation at the 2023 European Society for Medical Oncology (ESMO) Congress.

Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer

First readout of two-year data from long-term extension study INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company (NYSE: LLY). Results from ADjoin will be presented at the 43rd Annual Fall Clinical Dermatology Conference happening from October 19-22 in Las Vegas, Nevada.1  "Lebrikizumab, administered with a once-monthly dose following an induction phase, demonstrated efficacy for patients with moderate-to-severe atopic dermatitis, offering sustained relief from some of the most distressing signs and symptoms of the disease," said Emma Guttman-Yassky, M.D.

Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years

Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported on Friday, citing a person familiar with the matter.

Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg

Hundreds of online sellers are offering Eli Lilly' & Co.'s LLY, -2.71% retatrutide weight-loss drug for sale, even though the drug is years away from gaining regulatory approval, the Wall Street Journal reported Friday based on its own review of the matter. The bulk of the sellers appears to be Chinese who are shipping directly to U.S. consumers from sites such as one called Made-in-China.com.

Hundreds of online sellers are offering an Eli Lilly weight-loss drug that's years away from regulatory approval: WSJ

Eli Lilly on Thursday said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro, which is expected to be approved for weight loss later this year.

Eli Lilly sues online pharmacies to ban US imports of fake Mounjaro

Bristol-Myers

Johnson & Johnson

McKesson

Pfizer

Procter & Gamble

Walgreens

This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.

7 Healthcare Stocks That Can Cure a Lackluster Portfolio

Eli Lilly has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday.

Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source

Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.

1 Market-Beating Stock to Buy Near Its 52-Week High

Realty Income Corp

Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.

4 Ways to Grow $100,000 Into $1 Million for Retirement

Leadership from Eli Lilly and Novo Nordisk have alluded that it could take several quarters or even years to catch up with demand. Both companies are ratcheting up supply output, which will likely lead to high manufacturing costs.

1 Thing You'd Better Know Before You Invest in the Stocks Behind Ozempic and Mounjaro

Visa

The hunt for the next trillion-dollar companies invariably ignites investor excitement. Moreover, the AI-led excitement in equities this year pushed tech stocks to new highs while others reversed the losses from the past year.

The Next Trillion-Dollar Companies: 3 Stocks to Buy Now

The pending acquisition reflects the potential of Mablink's existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates.

Mablink Bioscience Enters an Agreement to be Acquired by Lilly

Eli Lilly & Co (NYSE: LLY) is buying Mablink Bioscience – a French biotechnology company that focuses primarily on the next-generation, antibody-drug conjugates for cancer. It's the 2nd cancer company Lilly bought this month Clearly, the pharmaceutical behemoth is committed to expanding its footprint in oncology.

Eli Lilly is buying another European cancer firm Mablink Bioscience

DexCom

Edwards Lifesciences

iShares U.S. Medical Devices ETF

Inspire Medical Systems Inc

Intuitive Surgical

Insulet

ResMed

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

Novo Nordisk recently raised its full-year 2023 guidance in large part because of greater sales expectations for Ozempic. The same dynamics behind Ozempic's success are also helping Lilly's Mounjaro.

Ozempic Sales Are Skyrocketing Faster Than Expected. Here's Why That's Great News for Eli Lilly Stock.

Alphabet

Microsoft

NVIDIA

Tesla

Taiwan Semiconductor Manufacturing

They say we're now living in an “age of acceleration” when technological advances are coming at us at breakneck speed. Not long ago, science fiction films and novels depicted a future when we would speak to computers and they would speak back, people would take a pill each day to remain thin and private companies would shuttle astronauts and supplies into space.

7 Cutting-Edge Stocks That Could Change Humanity as We Know It

The full results of the SURMOUNT-3 trial were published in Nature Medicine and simultaneously presented at ObesityWeek ®  2023 INDIANAPOLIS , Oct. 15, 2023 /PRNewswire/ -- Detailed results from Eli Lilly and Company's (NYSE: LLY) phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in Nature Medicine  and simultaneously presented at ObesityWeek® 2023. Tirzepatide met both co-primary endpoints for the efficacy estimandi and treatment-regimenii estimand, demonstrating superiority to placebo during the 72-week double-blind treatment period.

Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks

News for Eli Lilly Stock (LLY)